Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Vaccine. 2018 Aug 28;36(36):5350-5357. doi: 10.1016/j.vaccine.2017.07.062. Epub 2017 Jul 31.
At the current time, the field of vaccinology remains empirical in many respects. Vaccine development, vaccine immunogenicity, and vaccine efficacy have, for the most part, historically been driven by an empiric "isolate-inactivate-inject" paradigm. In turn, a population-level public health paradigm of "the same dose for everyone for every disease" model has been the normative thinking in regard to prevention of vaccine-preventable infectious diseases. In addition, up until recently, no vaccines had been designed specifically to overcome the immunosenescence of aging, consistent with a post-WWII mentality of developing vaccines and vaccine programs for children. It is now recognized that the current lack of knowledge concerning how immune responses to vaccines are generated is a critical barrier to understanding poor vaccine responses in the elderly and in immunoimmaturity, discovery of new correlates of vaccine immunogenicity (vaccine response biomarkers), and a directed approach to new vaccine development. The new fields of vaccinomics and adversomics provide models that permit global profiling of the innate, humoral, and cellular immune responses integrated at a systems biology level. This has advanced the science beyond that of reductionist scientific approaches by revealing novel interactions between and within the immune system and other biological systems (beyond transcriptional level), which are critical to developing "downstream" adaptive humoral and cellular responses to infectious pathogens and vaccines. Others have applied systems level approaches to the study of antibody responses (a.k.a. "systems serology"), [1] high-dimensional cell subset immunophenotyping through CyTOF, [2,3] and vaccine induced metabolic changes [4]. In turn, this knowledge is being utilized to better understand the following: identifying who is at risk for which infections; the level of risk that exists regarding poor immunogenicity and/or serious adverse events; and the type or dose of vaccine needed to fully protect an individual. In toto, such approaches allow for a personalized approach to the practice of vaccinology, analogous to the substantial inroads that individualized medicine is playing in other fields of human health and medicine. Herein we briefly review the field of vaccinomics, adversomics, and personalized vaccinology.
目前,疫苗学在许多方面仍然是经验性的。疫苗的开发、疫苗的免疫原性和疫苗的功效在很大程度上一直受到经验主义的“分离-灭活-注射”范式的驱动。反过来,一种针对疫苗可预防传染病的人群水平公共卫生范式,即“为每个人针对每种疾病提供相同剂量”的模式,一直是预防疫苗可预防传染病的规范思维。此外,直到最近,还没有专门设计的疫苗来克服衰老的免疫衰老,这与二战后为儿童开发疫苗和疫苗计划的心态一致。现在人们认识到,目前对疫苗免疫反应是如何产生的知识的缺乏是理解老年人和免疫不成熟人群中疫苗反应不佳的一个关键障碍,也是发现疫苗免疫原性的新相关性(疫苗反应生物标志物)和新疫苗开发的有针对性方法的一个关键障碍。疫苗组学和逆境组学的新领域提供了模型,允许在系统生物学水平上对固有、体液和细胞免疫反应进行全面分析。这一科学的进步超越了还原论科学方法,揭示了免疫系统内部和其他生物系统(超越转录水平)之间的新相互作用,这些相互作用对于开发对传染病病原体和疫苗的“下游”适应性体液和细胞反应至关重要。其他人已经将系统水平的方法应用于抗体反应的研究(又称“系统血清学”),[1]通过 CyTOF 进行高维细胞亚群免疫表型分析,[2,3]以及疫苗诱导的代谢变化[4]。反过来,这些知识被用于更好地理解以下内容:确定谁面临哪种感染的风险;免疫原性差和/或严重不良事件的风险程度;以及充分保护个体所需的疫苗类型或剂量。总的来说,这些方法允许对疫苗学实践进行个性化的方法,类似于个体化医学在人类健康和医学的其他领域所取得的重大进展。在此,我们简要回顾疫苗组学、逆境组学和个性化疫苗学领域。